// App-Quantinova.ai

3178 : Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM)

Researchers

Presenter

  • Shaji Kumar

Principal Investigators

  • Francis K Buadi

  • Shanmugapriya Saravanan

  • Iwen Pan

  • Debra Rembert

  • Rahul Dhanda

  • Liviu Niculescu

  • Abbie Ba-Mancini

  • Esprit Ma

  • Maureen Quick

  • S. Vincent Rajkumar

  • Martha Q Lacy

  • Angela Dispenzieri

  • Mei Sheng Duh

  • Marie-Helene Lafeuille

  • Patrick Lefebvre

  • Wendy Y Cheng

  • Katherine Dea

  • Mark Yap

Medical Centers

  • McKesson Specialty Health, The Woodlands, TX

  • McKesson Specialty Health/US Oncology Network, The Woodlands, TX

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

  • Groupe d'analyse, Ltee, Montreal, QC, Canada

  • Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN

Locations

  • United States

  • Canada

Companies

  • Takeda Pharmaceutica

  • Analysis Group, Inc.

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Congestive heart failure

  • Peripheral neuropathy

  • Renal insufficiency

  • Diabetes

  • Multiple Myeloma

  • Thrombocytopenia

  • Neutropenia

  • Venous thrombosis

  • Anemia

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Bortezomib

Outcome

  • N/A

Study Design

  • observational

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved